PrognomiQ Inc

PrognomiQ Inc. is dedicated to transforming healthcare through advanced biotechnology research. Leveraging the power of multi-omics data, PrognomiQ aims to revolutionize early disease detection and treatment. The company focuses on generating proteomic information with unparalleled accuracy, scale, and speed, complemented by genomic, metabolomic, and other essential health data. This comprehensive approach allows PrognomiQ to develop first-in-class test products that address diseases at their earliest, most treatable stages.

Located at 1900 Alameda de Las Pulgas, Suite 100, San Mateo, California 94403, US, PrognomiQ is committed to unlocking previously untapped disease insights by building on a robust proteomics foundation. Addressing technical and economic barriers that have historically limited broad-scale proteomics analyses, PrognomiQ utilizes next-generation tools to elucidate complex proteomics at scale. By integrating new sources of proteomics data with genomics and metabolomics, PrognomiQ is creating powerful multi-omics data sets that will be pivotal in detecting and treating diseases proactively.

PrognomiQ Inc. is at the forefront of innovation, designing a proprietary multi-omics platform that incorporates the most robust approaches to generating proteomic, genomic, and metabolomic data at scale. PrognomiQ spun out of the life science tools company Seer in 2020 and continues to push boundaries in biotechnology research. We invite the manager of PrognomiQ Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance their visibility and commercial opportunities.